Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

FDA Grants Full Approval to AbbVie’s Elahere for Advanced Ovarian Cancer Treatment

Fineline Cube Mar 26, 2024

This week, the U.S. Food and Drug Administration (FDA) granted full approval to AbbVie’s (NYSE:...

Company Deals Hospital

Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services

Fineline Cube Mar 26, 2024

China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s...

Company Deals Drug

Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development

Fineline Cube Mar 26, 2024

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South...

Company Deals

HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups

Fineline Cube Mar 26, 2024

China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science...

Company Drug

CanSino Biologics Launches Phase III Study for Menhycia Vaccine in Indonesia

Fineline Cube Mar 26, 2024

China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study...

Company Deals

Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio

Fineline Cube Mar 26, 2024

Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a...

Company

Kelun-Biotech Reports Robust 91.6% Revenue Growth Amid Strategic Licensing Efforts

Fineline Cube Mar 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) reported its 2023 financial results, revealing revenues of...

Company Drug

Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225

Fineline Cube Mar 26, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based biopharmaceutical company, has announced promising top-line...

Company Medical Device

Zylox-Tonbridge Secures NMPA Approval for Advanced Flow Diverter Targeting Intracranial Aneurysms

Fineline Cube Mar 26, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Deals

Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe

Fineline Cube Mar 26, 2024

Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with...

Company

WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business

Fineline Cube Mar 26, 2024

WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Jiangsu Hengrui’s Generic Version of Tepadina Approved for Transplantation Conditioning in China

Fineline Cube Mar 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC

Fineline Cube Mar 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...

Company

Sandoz Expands Antibiotics Production with New Austrian Factory

Fineline Cube Mar 25, 2024

Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics...

Company Drug

Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments

Fineline Cube Mar 25, 2024

Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...

Company Drug

EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision

Fineline Cube Mar 25, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company

Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market

Fineline Cube Mar 25, 2024

Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of...

Company

Roche Invests EUR 90 Million in New Gene Therapy Center in Germany

Fineline Cube Mar 25, 2024

Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in...

Company Drug

Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges

Fineline Cube Mar 25, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...

Company Drug

FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia

Fineline Cube Mar 25, 2024

FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it...

Posts pagination

1 … 436 437 438 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.